Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Sees Ever-Expanding Customer Base for DehydraTECH Drug Delivery Platform

• Lexaria Bioscience recently announced its DehydraTECH(TM) patent for pharmaceutical applications of cannabinoids to treat certain disease conditions
• Lexaria Bioscience’s patented DehydraTECH drug delivery platform can be used to deliver nicotine, cannabinoids and many other useful substances
• The company has roughly 60 patents pending in countries around the world for its DehydraTECH drug delivery platform

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is at the forefront of the development of useful biotechnology products and has played a pivotal role in developing a way to deliver substances to the brain via non-inhalation methods through the development of a novel drug delivery platform.

The DehydraTECH drug delivery platform was developed by Lexaria Bioscience Corp. and has already received patents in both the United States and Australia, most recently for pharmaceutical applications of cannabinoids to treat certain disease conditions (http://ibn.fm/gRhN0). In addition, patents are also pending in over 40 countries around the world. The delivery method can be used in a variety of forms, including in edible foods and beverages, and the technology has several benefits and applications for the pharmaceutical industry.

This innovative technology can be used to safely deliver nicotine and a range of other substances, including cannabidiol, to the body via ingestion rather than inhalation. It has been recognized that inhalation is dangerous and associated with other medical problems. Thus, finding an alternative means for the effective and safe delivery of substances which have traditionally been inhaled is advantageous. A total of nine corporations have signed 11 definitive contracts to use Lexaria’s revolutionary DehydraTECH drug delivery platform, and its client base continues to expand exponentially.

It is clearly a benefit to find and use edible or drinkable products as a way of delivering substances to the bloodstream. It is also beneficial that the delivery system works in beverages, for individuals who may be having trouble eating solid foods. Consequently, new patent applications related to the recent innovations have been filed by Lexaria (http://ibn.fm/aXdDw).

This patented delivery system works in such a way that the required substance can be absorbed by the gastrointestinal system. This is an important development, since previous edible products containing substances such as nicotine were found to be poorly absorbed from the gut, which meant that they were not very effective for the purposes of delivering the nicotine in a safe manner. In addition, no sugar additives are needed, since this product blocks any unpleasant or bitter taste. This is a big benefit, because it means that unhealthy taste-enhancing substances do not need to be added to products to make them palatable. The DehydraTECH drug delivery platform also enables the substances to bypass first phase liver metabolism.

Lexaria’s DehydraTECH drug delivery platform has been shown to rapidly deliver nicotine and cannabidiol to the brain. In general, the ingestion of nicotine and cannabinoids in this way means that far more of the substance is absorbed than through other means of edible ingestion, which is a distinct advantage. Lexaria, through its relationship with Canada’s National Research Council (“NRC”), also continues to investigate what interactions take place at the molecular level between nicotine polacrilex formulations and DehydraTECH’s methodology in order to continually improve on DehydraTECH and expand scientific understanding of its processes.

The platform does work very well in delivering non-psychoactive cannabinoids, which have been recognized as beneficial in treating many ailments (http://ibn.fm/dr6Py). In a human clinical test, DehydraTECH achieved a 319 percent higher CBD blood concentration compared with other systems within 30 minutes of ingestion.

Cannabidiol is a helpful substance that has potential for the treatment of many medical conditions, and a quick uptake of the substance is important in people who desire rapid relief of unpleasant symptoms such as nausea and pain. The CBD acts on special receptors in the brain which causes changes in how the nervous system functions (http://ibn.fm/ZBpdf).

There is scientific evidence to substantiate many of the health benefits of CBD. Besides helping to alleviate symptoms of nausea, CBD has been found to work well in patients who have seizure disorders such as Dravet syndrome and Lennox-Gastaut syndrome, which are difficult to treat by conventional means. The cannabinoid also helps with pain and even anxiety.

Inhalation may be a quicker route for getting cannabinoids and certain other substances into the brain, but it is harmful to the body, which is why this new delivery technology is preferable. Lexaria Bioscience Corp. has 16 patents granted for DehydraTECH for the safe, rapid and effective delivery of cannabidiol.

A further advantage of the platform is that several other fat-soluble substances can be delivered using the DehydraTECH drug delivery platform. For instance, the DehydraTECH delivery system can be used for the rapid delivery and gastrointestinal uptake of substances including fat-soluble vitamins, such as vitamin A and E, and non-steroidal anti-inflammatory drugs, such as acetylsalicylic acid and ibuprofen. There is also potential for the use of DehydraTECH to deliver drugs that can help with nervous system disorders such as Alzheimer’s disease. This is helpful, since the blood-brain barrier has sometimes been an obstacle for the delivery of drugs to the brain. Lexaria attributes its recent commercial success largely to its rapidly expanding body of scientific results that prove the superior capabilities of its patented technologies.

For more information, visit the company’s website at www.LexariaBioscience.com

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Issues Corporate Update; Set to Present at H.C. Wainwright 21st Annual Global Investment Conference

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) on Tuesday issued an update regarding its clinical development programs, manufacturing and strategy for bringing its Oncoprex(TM) immunogene therapy to market. A corporate presentation is available on GNPX’s website which details anticipated milestones and future guidance for the company. “These milestones emphasize our commitment to developing potentially life-changing gene technologies for cancer patients who need them most,” Genprex chairman and chief executive officer Rodney Varner stated in the news release. “We continue to dedicate our efforts toward developing Oncoprex for non-small cell lung cancer (“NSCLC”) and we believe that achievement of these milestones will enable us to advance our gene therapy platform and position us to bring our drug candidate to commercialization.” In addition, GNPX this morning announced that it will be presenting at the H.C. Wainwright 21st Annual Global Investment Conference in New York City at 3:00 PM ET on Tuesday, September 10, 2019. Genprex chairman and chief executive officer Rodney Varner will lead the presentation and will be available for one-on-one meetings. To set a meeting, contact the company at Investors@Genprex.com.

To view the full press releases, visit http://ibn.fm/uBE4R and http://ibn.fm/1p5ES

About Genprex, Inc.

Genprex, Inc. is a clinical stage gene therapy company developing potentially life-changing technologies for cancer patients, based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex(TM) immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. For more information, visit the company’s website at www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) Welcomes New Investors, Releases Update on Aurora Ownership

Cannabis-focused research and development company The Green Organic Dutchman Holdings (TSX: TGOD) (OTCQX: TGODF) today commented on the recent transaction between Aurora Cannabis (TSX: ACB) and a syndicate of Canadian banks. Per the update, the block trade was executed on September 3 after market close and resulted in the exchange of a total of 28.8 million shares, each at a negotiated price of $3.00. The Edmonton-based company continues to retain a large number of TGOD warrants equivalent to approximately 5% of its fully diluted shares, and the transaction significantly improves TGOD’s revenue and gross margin mix due to the repatriation of TGOD’s premium organic cannabis previously earmarked for Aurora under an agreement between the parties. “Aurora has been an excellent partner during TGOD’s initial development phase; their investment played an important role in our success. The relationship added significant value across multiple areas of the business, including the initial design and construction of our Canadian facilities,” TGOD CEO Brian Athaide said in the news release. “This is the right next step in the relationship as both companies mature and our respective strategies evolve. It also improves TGOD’s revenue and margin potential on the sale of our premium organic cannabis.”

To view the full press release, visit http://ibn.fm/m7SGQ

About the Green Organic Dutchman Holdings Ltd.

The Green Organic Dutchman is a publicly traded, premium, global organic cannabis company with operations focused on medical cannabis markets in Canada, Europe, the Caribbean and Latin America, as well as the Canadian adult-use market. TGOD also has organic-hemp CBD oil operations in Canada and through its wholly owned subsidiary HemPoland, which distributes premium-hemp CBD oil in the EU. The company grows high-quality, organic cannabis with sustainable, all-natural principles. TGOD’s products are laboratory tested to ensure patients have access to a standardized, safe and consistent product. TGOD has a planned capacity of 219,000 kgs and is building 1,643,600 square feet of cultivation and processing facilities across Ontario, Quebec, Jamaica and Denmark. For more information, visit the company’s website at www.TGOD.ca.

NOTE TO INVESTORS: The latest news and updates relating to TGODF are available in the company’s newsroom at http://ibn.fm/TGODF 

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Rolls Out Online Sales of Discrete Powdered Formulation of CBD-Rich Hemp Oil

• Lexaria Bioscience is an innovator in the field of bioavailable lipophilic active compounds, and it is working to make consumption of certain products through oral ingestion a viable alternative to inhalation
• A particular focus of the company’s technology is to ensure that cannabinoids can enter the blood stream at speeds comparable to smoking and can be used in a discrete manner
• Cannabis-infused beverage sales are expected to surpass $1.4 billion by 2024, marking a nearly 15-fold increase over 2018 levels

Drug bio-delivery technology innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has launched online commercial delivery of the cannabis industry’s most advanced water-soluble multi-spectrum hemp oil in a powdered format, making high-quality hemp oil with cannabidiol (CBD) readily available to meet the beverage infusion needs of consumers in the United States.

The company’s August 22 announcement (http://ibn.fm/Ljt7D) states that its ChrgD+ product is powered by Lexaria’s proprietary DehydraTECH(TM) technology for rapid CBD delivery to the user’s bloodstream within 15 minutes – sometimes as fast as two minutes in lab testing.

The rapid bio-delivery of CBD through DehydraTECH provides an avenue for safer, less conspicuous consumption of CBD than inhaling it through smoke or vapor during a critical time when social acceptance of cannabis products is exploding age-old prohibitions but many legislative entities continue to struggle with regulatory issues on behalf of the public welfare.

ChrgD+ has been available in a limited number of retail stores throughout the western United States, but the announcement that it is now available via commercial web delivery to locations where it can be legally consumed means that anyone has the potential to obtain it through the website www.ChrgD.life without having to travel. Limited-time promotional offers and product updates are also available through the site.

Each serving of ChrgD+ weighs just two grams, making it easy for a consumer to carry multiple servings in a shirt pocket or athletic wear while on the go. The multi-spectrum oil-based powder can be poured innocuously into any hot or cold beverage, and every package contains a manufacturing batch code that makes it simple for consumers to browse lab test results for the actual potency of the package’s ingredients (which contain no THC) as part of Lexaria’s push for transparency.

DehydraTECH technology provides the added benefit of gently removing unpleasant cannabis flavors, so ChrgD+ is able to avoid the artificial flavors or sweeteners that other products may use to mask the strong flavors and aromas inherent to hemp oil.

These innovations are examples of Lexaria’s ongoing mission to enhance the “speed of action, flavor and gastro-intestinal delivery of orally-administered products,” particularly those that utilize cannabinoids, nicotine and ibuprofen.

Zenith Global’s industry analysts predict that the U.S. market for cannabis- and hemp-infused drinks will reach more than $1.4 billion by 2024, almost 15-times the 2018 level, as part of an overall trend toward life-enhancing practices that focus on alternatives to traditional medicines and recreational products, including alcoholic beverages and tobacco products (http://ibn.fm/V6ucn).

With the federal legalization of edible cannabis products only a month away in Canada, Lexaria is also preparing to roll out DehydraTECH-licensed products in collaboration with alcohol-free beer, wine and adult format beverage maker Hill Street Beverage Company Inc. (TSX.V: BEER) on a first-time business-to-business (B2B) basis between Canada’s licensed producers and other businesses licensed by Health Canada to make cannabis-infused edibles. The as-yet unnamed new brand will feature processed tetrahydrocannabinol (THC) and/or CBD powder from cannabis or its less chemically psychoactive hemp variant as part of the companies’ efforts to build production in a new market space.

For more information, visit the company’s website at www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Earth Science Tech Inc. (ETST) Reports 36% Revenue Gain, 90% Jump in Gross Profit for Quarter Ended June 30

• ETST reported $227,635 in revenue for the quarter ended June 30, 2019, marking a greater than 36 percent hike when compared to $166,891 for the same period in 2018
• The company’s gross profits spiked by more than 90 percent for the three-month period to $113,126, up from $59,409 for the same period in 2018
• ETST grew its revenue while cutting key operating expenses related to R&D, legal and marketing

Earth Science Tech Inc. (OTCQB: ETST), a diverse biotech company focused on the nutraceutical and pharmaceutical fields, reported sharply higher revenue and gross profit for the three months ended June 30, 2019. Notably, the company recorded a higher than 90 percent gain in gross profit for the 2019 period, alongside increased revenue totals and decreased operating expenses (http://ibn.fm/WSgql).

For the quarter, ETST reported sales of $227,635 – a total that is 36.4 percent higher than the $166,891 in revenues for the comparable period in 2018. Additionally, gross profit jumped to $113,126 in the 2019 quarter, from $59,409 for the same quarter in 2018. To achieve that higher gross profit figure, ETST placed emphasis on cutting key operating expenses, including marketing, legal and R&D.

The ETST report detailed those cuts, including dropping R&D expenses to $22,113 as compared to $65,245 for the same period in 2018. The decrease in 2019 is primarily associated with the company moving its Hygee(TM) medical device out of R&D phase and discontinuing CBD patent applications, per a corporate update. Hygee is a revolutionary home kit designed for the detection of sexually transmitted infections, such as chlamydia, in women. The company sees Hygee as empowering women across the globe while setting a new standard in women’s health. The product has already generated excitement among investors. In other efforts to improve its bottom line, ETST has also been taking a hard look at its marketing expenses. By eliminating magazine marketing, the company was able to decrease these costs to $20,623 in the three-month period, down from $29,267 in the comparable period of 2018.

Those revenue and gross profit gains for the quarter came after ETST earlier reported that product sales were $770,635 for its fiscal year ended March 31, 2019, marking a 66.4 percent increase compared to the $463,108 recorded for the same period in 2018. The company was able to maintain a gross profit total of $295,013 and a gross margin of 38.2 percent in 2019, with full-spectrum cannabinoids driving sales. The company also reported that its core customer base grew as a result of the positive response to its V4 product line (http://ibn.fm/0kclZ).

ETST continues to synergize a passion for health and wellness with its premium products. In a July 2019 SEC filing, ETST management explained that its market advantage strategy is “to design and produce CBD-enhanced nutraceutical products for sale to the general public. (The company) intends to create high-grade, CBD-rich hemp oil and other CBD-containing products unique to the current market in the nutraceuticals industry. (It) believes that (its) formulations will set (ETST) apart from competing products for promoting health.”

The company markets a complete line of high-grade hemp-CBD oils, hemp-CBD caps and CBD pet oil products, with its full-spectrum and pure CBD oils utilizing a super-critical CO2, cold-liquid extraction method.

For more information, visit the company’s website at www.EarthScienceTech.com

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at http://ibn.fm/ETST

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Predictive Oncology Inc. (NASDAQ: POAI) is “One to Watch”

• Helomics is collaborating with the University of Pittsburgh School of Medicine to study the use of artificial intelligence to improve clinical decision making for ovarian cancer patients. More than 22,000 women are diagnosed with ovarian cancer in the U.S. each year.
• Entered an agreement with Interpace Diagnostics Group Inc. (IDXG) and Helomics to develop products to diagnose and assess the risk for thyroid cancer as well as provide appropriate therapeutic recommendations. The treatment market for thyroid cancer is expected to reach $2.1 billion by 2025.
• Skyline Medical has received its first order for four STREAMWAY machines to be sold to local hospitals in India. The Indian healthcare industry is estimated at more than $100 billion, with the nation’s medical device industry valued at more than $6 billion.
• Helomics signed a collaborative research agreement with Pittsburgh-based molecular imaging company, ChemImage, to expand personalized medicine to prostate cancer diagnosis and treatment.
• TumorGenesis and partner 48Hour Discovery received the Alberta Innovates grant for development of novel cancer treatments.

Predictive Oncology Inc. (NASDAQ: POAI) is a data and artificial intelligence-driven discovery services company that provides predictive models of tumor drug response to improve patient outcome. Predictive Oncology harnesses the power of artificial intelligence, collaborating with the pharmaceutical, diagnostic and biotech industries to develop highly customizable assessment methods for patients, which can lead to much more effective treatments.

Subsidiaries

Predictive Oncology leverages the synergies of its three wholly owned subsidiaries to bring precision medicine to the diagnosis of cancer.

Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomic’s CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy.

In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™ patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary platform (D-CHIP) to provide a tailored solution to its clients’ specific needs.

TumorGenesis is developing a new, rapid approach to growing tumors in the laboratory, which essentially “fools” cancer cells bind to specific biomarkers. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and help categorize an individual patient’s heterogeneous tumor samples to enable development of patient specific treatment options.

Skyline Medical’s patented, FDA-cleared STREAMWAY System is the first true, direct-to-drain fluid disposal system designed specifically for medical applications such as radiology, endoscopy, urology and cystoscopy procedures. The STREAMWAY system is changing the way healthcare facilities collect and dispose of potentially infectious waste fluid by connecting directly to a facility’s plumbing system to automate the collection, measurement and disposal of waste fluids.

The STREAMWAY minimizes human intervention for better safety and improves compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines. The STREAMWAY eliminates canisters, carts and evacuated bottles, which reduces overhead costs and minimizes environmental impact by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the United Sates.

Skyline has achieved sales in five of the seven continents through both direct sales and distributor partners.

Leadership Team

Dr. Carl Schwartz was appointed to Skyline Medical’s board of directors in March 2015 and became interim president and CEO in May 2016. He has owned and managed dental groups in Michigan and currently owns two dental practices there. Dr. Schwartz became CEO of Plastics Research Corporation in 1988, leading the company to become the largest manufacturer of structural foam molding products in the U.S. with more than $60 million in revenues and 300 employees by the time he retired in 2001. He holds a bachelor’s degree and DDS degree from the University of Detroit.

CFO Bob Myers has over 30 years of experience in multiple industries focusing on medical device service and manufacturing. He has spent much of his career as a CFO and controller. Myers holds an MBA in Finance from Adelphi University and a BBA in public accounting from Hofstra University.

For more information, visit the company’s website at www.Predictive-Oncology.com

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) Receives Health Canada Approval to Expand Operations into Hamilton Hybrid Greenhouse

Cannabis-focused research and development company The Green Organic Dutchman Holdings (TSX: TGOD) (OTCQX: TGODF) today announced its receipt of Health Canada approval, under the Cannabis Regulations, to expand operations into its new Hamilton, Ontario-based hybrid greenhouse. According to the update, the state-of-the-art 123,000 square foot facility will serve to increase TGOD’s premium organic cannabis production as it expands sales in Canada. “We are thrilled to start using this purpose-built hybrid greenhouse as we ramp up our production of premium organic cannabis, an underserved segment of the market,” TGOD CEO Brian Athaide stated in the news release. “Our team pioneered the concept of growing organic cannabis at scale; this hybrid greenhouse has been artfully designed for organic cultivation, allowing us to reliably produce clean, safe and non-irradiated cannabis.”

To view the full press release, visit http://ibn.fm/Jpt5A

About the Green Organic Dutchman Holdings Ltd.

The Green Organic Dutchman is a publicly traded, premium, global organic cannabis company with operations focused on medical cannabis markets in Canada, Europe, the Caribbean and Latin America, as well as the Canadian adult-use market. TGOD also has organic-hemp CBD oil operations in Canada and through its wholly owned subsidiary HemPoland, which distributes premium-hemp CBD oil in the EU. The company grows high-quality, organic cannabis with sustainable, all-natural principles. TGOD’s products are laboratory tested to ensure patients have access to a standardized, safe and consistent product. TGOD has a planned capacity of 219,000 kgs and is building 1,643,600 square feet of cultivation and processing facilities across Ontario, Quebec, Jamaica and Denmark. For more information, visit the company’s website at www.TGOD.ca.

NOTE TO INVESTORS: The latest news and updates relating to TGODF are available in the company’s newsroom at http://ibn.fm/TGODF 

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html